RTL 1000

Drug Profile

RTL 1000

Alternative Names: RTL1000; VG1000

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oregon Health & Science University
  • Developer Artielle ImmunoTherapeutics
  • Class
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 18 May 2016 Phase I development is ongoing in USA
  • 19 Apr 2010 Final adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in relapsing-remitting multiple sclerosis presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN-2010)
  • 14 Sep 2009 Efficacy and Adverse Event data from a phase I trial in Multiple sclerosis presented at the 13th Congress of the European Federation of Neurological Societies(EFNS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top